Asamedic is a Norwegian pharmaceutical company established in 2015 with the purpose of developing a drug against acute myocardial infarction.
The result became Coxor®, developed between 2015 – 2022, and launched with success in Norway in 2023 following approval in a European DCP.
Coxor® is patented in most parts of the world, and licensed by several well known pharmaceutical companies.
From founding in 2013 to the launch of Coxor® and global licensing.
The people leading Asamedic into the next phase.
The companies we work with to bring Coxor® to patients.
